CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 153 enrolled
Drug / intervention
Pycnogenol® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05890534
NCT05890534Phase 3Completed
CompareCT.gov

Pycnogenol® in People With Post-COVID-19 Condition: a Quadruple-blind, Randomized, Placebo-controlled Trial

University of Zurich·interventional·Posted Jun 6, 2023·Updated Apr 29, 2026

In Brief

A Phase 3 clinical trial evaluating Pycnogenol® and Placebo for Post COVID-19 Condition and Long COVID. Completed, enrolled 153 participants across 1 site.

Detailed Summary

To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost COVID-19 Condition, Long COVID
CountriesSwitzerland
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedJun 6, 2023
Enrollment StartJun 7, 2023
Primary CompletionNov 5, 2024
Study CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.1 years ago

Interventions

Pycnogenol®drug

Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.

Placebodrug

Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.